2023
DOI: 10.1002/jia2.26077
|View full text |Cite
|
Sign up to set email alerts
|

Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

Abstract: Introduction Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(3 citation statements)
references
References 17 publications
(21 reference statements)
0
3
0
Order By: Relevance
“…The advancement of LA-PrEP can make significant progress toward ending the HIV epidemic in the U.S. compared to oral PrEP alone [ 13 , 14 ]. LA-PrEP brings opportunities to overcome barriers of oral PrEP related to convenience and privacy [ 15 17 ]. However, most of what we know about the acceptability of LA-PrEP is from studies conducted pre-licensure [ 16 , 18 21 ].…”
Section: Introductionmentioning
confidence: 99%
“…The advancement of LA-PrEP can make significant progress toward ending the HIV epidemic in the U.S. compared to oral PrEP alone [ 13 , 14 ]. LA-PrEP brings opportunities to overcome barriers of oral PrEP related to convenience and privacy [ 15 17 ]. However, most of what we know about the acceptability of LA-PrEP is from studies conducted pre-licensure [ 16 , 18 21 ].…”
Section: Introductionmentioning
confidence: 99%
“…In studies of PrEP interest and acceptability, once they become aware of PrEP including the long-acting injection, Latino/a/x sexual minority men and transgender women reported willingness to adopt PrEP at the same or higher levels than their non-Latino/a/x peers [ 12 , 19 ]. These studies revealed that improving awareness of PrEP is key to reducing disparities in PrEP uptake among Latino/a/x individuals.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to ARTs, pre-exposure prophylaxis (PrEP) is a highly effective medication, that when taken as prescribed, is highly effective for preventing HIV infection, including for those at risk through sex or injection drug use ( 4 ). Importantly, certain sexual and gender minorities (SGMs), including men who have sex with men (MSM) and transgender women, have been disproportionately impacted by HIV infection and may have different attitudes toward PrEP therapy that can impact uptake and adherence ( 5 , 6 ). Understanding the willingness to use PrEP therapy among these at-risk SGM populations, including in the context of drug transition and switching behavior, is critical to reducing HIV incidence.…”
Section: Introductionmentioning
confidence: 99%